Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711929 | 1.00 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4NLRP3 | |
| SCHEMBL22808748 | 0.89 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19010129 | 0.88 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20334859 | 0.86 | — | — | |
| SCHEMBL23841379 | 0.84 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21625293 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19295605 | 0.83 | — | — | |
| SCHEMBL21913977 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20711835 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25762055 | 0.83 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024138206-A1 | FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-7825118-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
| US-7732454-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | CHRNB2 4140/4885CHRNB4 4425/4885CHRNA3 4546/4885 |
| US-12029791-B2 | Therapeutic conjugates | CD47, CD44, EPCAM | CHRNB2 2251/4885CHRNB4 3060/4885CHRNA3 3324/4885 |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | CHRNB2 3963/4885CHRNB4 4297/4885CHRNA3 4254/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | CHRNB2 3963/4885CHRNB4 4297/4885CHRNA3 4254/4885 |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | CHRNB2 3963/4885CHRNB4 4297/4885CHRNA3 4254/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | CHRNB2 4614/4885CHRNB4 4709/4885CHRNA3 4767/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CHRNB2 4565/4885CHRNB4 4708/4885CHRNA3 4767/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | CHRNB2 4381/4885CHRNB4 4554/4885CHRNA3 4620/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CHRNB2 4214/4885CHRNB4 4580/4885CHRNA3 4523/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | CHRNB2 4019/4885CHRNB4 4223/4885CHRNA3 4296/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | CHRNB2 4637/4885CHRNB4 4468/4885CHRNA3 4260/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | CHRNB2 3646/4885CHRNB4 4503/4885CHRNA3 4663/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | CHRNB2 4624/4885CHRNB4 4462/4885CHRNA3 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.